August 18, 2022
HFpEF vs. HFrEF in patients with tricuspid regurgitation: does it matter for TTVr?
Speakers:
Chair: Stefan Anker, Carolyn Lam, Jeroen Bax, Andrew Coats, Barry Borlaug, Karl‑Patrik Kresoja
Join us:
ESC 2022
The countdown is on to the ESC Congress
At least 1 in 3 heart failure patients have significant mitral regurgitation (MR) or tricuspid regurgitation (TR) which significantly impacts responsiveness to medication, morbidity, and mortality.1-6
Transcatheter mitral and tricuspid valve therapies are emerging as safe and effective options to expand your toolbox to manage symptomatic patients no longer responding to GDMT.4-6
Join us at our symposium, where leading heart failure specialists and interventionalists will discuss their thoughts on patient selection for TR in heart failure. You can also head to our booth to find new resources to support you in caring for your patients.
Three days filled with the latest science in heart failure, evidence-based clinical guidance, expert discussions, and more
Be part of this year’s ESC Congress in Barcelona on 26–29 August to hear from our panel of experts. Start by clicking through to see our full 2022 session agenda and get to know each of our speakers.
Get Edwards updates
Join the Edwards Lifesciences community today to receive speaker decks from ESC 2022, and hear first about future events.
Register today for ESC Congress 2022 in Barcelona
If you would like to attend our symposium in person or online, you can use the following link.
Note: This link will take you to a third party site where there is a charge for attending the event.
ESC, European Society of Cardiology; GDMT, guideline-directed medical therapy; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MR, mitral regurgitation; TR, tricuspid regurgitation; TTVr, transcatheter tricuspid valve repair.
References:
- Chioncel O, Lainscak M, Seferovic PM, et al. Eur J Heart Fail. 2017;19(12):1574–1585.
- Rossi A, Dini FL, Faggiano P, et al. Heart. 2011;97(20):1675–1680.
- Messika-Zeitoun D, Verta P, Gregson J, et al. Eur J Heart Fail. 2020;22(10):1803–1813.
- Stone GW, Lindenfeld J, Abraham WT, et al. N Engl J Med. 2018;379(24):2307–2318.
- Mangieri A, Pagnesi M, Regazzoli D, et al. Front Cardiovasc Med. 2020;7:581211.
- Taramasso M, Benfari G, van der Bijl P, et al. J Am Coll Cardiol. 2019;74(24):2998–3008.
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult https://eifu.edwards.com/eifu )
Instructions For Use / Operator's Manual where applicable).
Edwards, Edwards Lifesciences, the stylized E logo, PASCAL, PASCAL Ace, and PASCAL Precision are trademarks or services marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners